TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by investment analysts at CIBC from a “market perform” rating to an “outperform” rating in a note issued to investors on Tuesday.

A number of other research analysts also recently weighed in on TXMD. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $15.00 target price on shares of TherapeuticsMD in a report on Monday, April 17th. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a report on Monday, April 24th. Zacks Investment Research downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, May 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $33.00 target price on shares of TherapeuticsMD in a report on Wednesday, May 10th. Finally, Jefferies Group LLC set a $15.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, June 14th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. TherapeuticsMD has a consensus rating of “Buy” and a consensus target price of $18.00.

TherapeuticsMD (NASDAQ:TXMD) traded up 8.33% during mid-day trading on Tuesday, hitting $5.20. 3,453,216 shares of the stock were exchanged. The stock has a 50 day moving average price of $4.62 and a 200 day moving average price of $5.62. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.39. The company’s market capitalization is $1.06 billion.

WARNING: “CIBC Upgrades TherapeuticsMD Inc (TXMD) to Outperform” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/11/cibc-upgrades-therapeuticsmd-inc-txmd-to-outperform.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. increased its position in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock worth $207,000 after buying an additional 10,330 shares in the last quarter. Greenwood Capital Associates LLC boosted its stake in shares of TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after buying an additional 3,022 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock worth $98,827,000 after buying an additional 329,245 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock worth $3,091,000 after buying an additional 238,885 shares during the last quarter. Finally, American International Group Inc. boosted its stake in shares of TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock worth $665,000 after buying an additional 6,103 shares during the last quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.